IL17A and COVID-19: The kinetics of the evaluated biomarkers among positive COVID-19 patients showed a significant reduction in most soluble mediators from the first evaluation after 30-days of SARS-CoV-2 infection to 180 days after symptom onset, except for CCL11, CXCL8, CCL3, CCL4, CCL5, IL-6, IFN-g, IL-17, IL-5, FGF-basic, PDGF, VEGF, G-CSF, and GM-CSF (Figs. 4 and 5).